

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 27, 2025

**BiomX Inc.**  
(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-38762**  
(Commission File Number)

**82-3364020**  
(IRS Employer  
Identification No.)

**22 Einstein St., Floor 4**  
**Ness Ziona, Israel**  
(Address of Principal Executive Offices)

**74140003**  
(Zip Code)

Registrant's telephone number, including area code: +972 723942377

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value	PHGE	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events.**

As previously disclosed, on February 25, 2025, BiomX Inc. (the "Company") entered into a series of transactions including a registered direct offering, a concurrent private placement, and the exercise of certain existing warrants (collectively, the "Offering"). The aggregate gross proceeds to the Company from the Offering were approximately \$12 million, before deducting placement agent fees and other offering expenses payable by the Company. The Offering closed on February 27, 2025. Following the closing of the Offering, as of March 5, 2025, the Company has 24,996,053 shares of its common stock issued and outstanding.

1

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 5, 2025

**BiomX Inc.**

By: /s/ Jonathan Solomon  
Name: Jonathan Solomon  
Title: Chief Executive Officer

2

